Journal
RSC MEDICINAL CHEMISTRY
Volume 14, Issue 4, Pages 692-699Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d2md00377e
Keywords
-
Ask authors/readers for more resources
A series of 1,3-oxazolo[4,5-d]pyrimidine and 1,3-oxazolo[5,4-d]pyrimidine derivatives were synthesized and tested against breast cancer cell lines. The compounds showed activity against most cell lines in the micromolar range and displayed correlation with tamoxifen and aclacinomycin A. Compound 1 effectively suppressed ADK in cultured MDA-MB 231 cell lines, suggesting it as a potential target for anticancer properties.
A series of 1,3-oxazolo[4,5-d]pyrimidine and 1,3-oxazolo[5,4-d]pyrimidine derivatives were synthesized and functionalized in this study. The obtained compounds were tested against breast cancer cell lines of the NCI subpanel, followed by further analysis using the COMPARE algorithm from the Therapeutics Development Program, NCI. All synthesized derivatives displayed activity against most cell lines in the range of micromolar concentrations in terms of all parameters studied. Oxazolopyrimidine 5 exhibited the highest antitumor activity. A standard COMPARE analysis of the compounds showed that the vectors of the cytotoxic activity of derivatives 10 and 11 displayed a close to very high correlation with tamoxifen, and oxazolopyrimidine 13 displayed a very high correlation with the same drug. Five derivatives (2, 4, 6, 11 and 13) showed a high correlation with aclacinomycin A in the TGI vector. At the same time, compound 1 effectively suppressed ADK in cultured MDA-MB 231 cell lines, indicating that ADK is one of its targets through which it exerts anticancer properties. Based on molecular docking results, the possible binding mode of oxazolopyrimidine 1 to ADK has been suggested.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available